Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate
製藥業2024年第一季度GAAP每股收益（0.02）未達到0.01美元的預期，5,5586萬美元的銷售額低於6,8425萬美元的預期
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 290 percent. This is unchanged from the same period last year. The company reported quarterly sales of $55.586 million which missed the analyst consensus estimate of $68.425 million by 18.76 percent. This is a 30.66 percent increase over sales of $42.541 million the same period last year.
製藥（納斯達克股票代碼：PHAR）公佈的季度虧損爲每股0.02美元，比分析師普遍預期的0.01美元低290％。這與去年同期相比沒有變化。該公司公佈的季度銷售額爲5,5586萬美元，比分析師普遍預期的6,8425萬美元低18.76％。這比去年同期的4,2541萬美元銷售額增長了30.66％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。